A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study Details
Study Description
Brief Summary
This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This is an open labeled, single center clinical study with placebo of historical researches as control. 10 patients will be enrolled in the study. The basic treatment is riluzole, 50mg twice a day. For the procedure, patients will take fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later, patients will repeat the fasudil treatment. All the patients will be followed up for 6 months. The primary outcome was the decline rate of ALSFRS-R. The secondary outcomes are the survival time, endpoint time(death, tracheotomy and continuous ventilator-dependent), forced vital capacity (FVC), the short form health survey (SF-36), evaluation of cognitive function (verbal fluency and Frontal Behavioral Inventory Scale) and safety.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Fasudil All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before. |
Drug: Fasudil
All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
|
Outcome Measures
Primary Outcome Measures
- The slope of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) score [Month 3, 6]
Secondary Outcome Measures
- Survival time [2 years]
Other Outcome Measures
- Forced Vital Capacity [Baseline, Month 3 and 6]
- SF-36 [Baseline, Month 3 and 6]
- Cognitive function [Baseline, Month 3 and 6]
verbal fluency and Frontal Behavioral Inventory Scale (FBI)
- Safety Labs [Baseline, Month 0.5, 3, 3.5, 6]
blood test including blood RT, liver function, renal function, serum electrolyte, myocardial enzyme, glucose and coagulation function
- Adverse Events [Month 0.5, 3, 3.5, 6]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical diagnosis of laboratory-supported probable, probable, or definite ALS
-
Age: 18-70 years
-
Disease duration: 3-36 months
-
Forced vital capacity: at least 60% of predicted
-
ALSFRS-R: at least 30, respiratory items: at least 10
-
Decline of ALSFRS-R in the last 3 months before enrollment: 1-8
-
Must take riluzole, on a stable dose for at least 30 days prior to baseline visit with no serious side effects. They must continue the riluzole treatment for at least 6 months after enrollment.
-
Patients of childbearing potential must be using an effective method of birth control
-
Willing and able to give informed consent
Exclusion Criteria:
-
Familial ALS
-
Pregnant or nursing women
-
Patients after tracheotomy or continuous ventilator-dependent (time with non-invasive ventilator more than 22 hours per day for 7 consecutive days.)
-
After percutaneous endoscopic gastrostomy
-
Alanine Transaminase (ALT) or Aspartate Transaminase (AST): at least 3 times the upper limit of normal
-
Abnormal creatinine or urea nitrogen
-
Severe cardiac disease, pulmonary disease, hematic disease, autoimmune disease, mental disease, dementia and substance abuse
-
History of malignancy
-
History of intracranial hemorrhage
-
History of severe bleeding of digestive tract, lungs, nose and skin
-
Allergic to fasudil
-
Participating in other clinical studies or using other investigational drugs at present
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Peking University Third Hospital | Beijing | China | 100191 |
Sponsors and Collaborators
- Peking University Third Hospital
Investigators
- Principal Investigator: Dongsheng Fan, MD, PhD, Peking University Third Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PUTH-2013121